BioSpace News Archive

Rapafusyn Pharmaceuticals Presents At The Second Annual Molecular Glue Summit In Boston, MA On January 31 - February 1

Rapafusyn Pharmaceuticals is pleased to announce two presentations at the Second Annual Molecular Glue Drug Discovery Summit

January 31, 2024
·
2 min read
FDA-Approved RENFLEXIS for Treatment of Multiple Autoimmune Diseases Now Distributed by BioCareSD

BioCareSD, a leading specialty distributor for orphan, rare and ultra-rare diseases, announced today that they have added RENFLEXISâ, a biosimilar to REMICADEâ, to their ever-expanding portfolio of therapies.

January 31, 2024
·
1 min read
Drug Development

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine

Intellia Therapeutics, Inc. announced that interim results from the Phase 1 portion of the Phase 1/2 study of NTLA-2002 were published online in the New England Journal of Medicine.

January 31, 2024
·
7 min read
Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany

Sandoz, the global leader in generic and biosimilar medicines, announces the launch of Tyruko® in Germany from February 1.

January 31, 2024
·
4 min read
Policy

Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand

Kuros Biosciences, a leader in next generation bone graft technologies, announced clearance of a 510 submission from the U.S. Food and Drug Administration related to its MagnetOs ™ Granules.

January 31, 2024
·
6 min read
AlzeCure CEO Martin Jönsson to Present at the International Investor Conference BioCapitalEurope

AlzeCure Pharma AB announced that its CEO Martin Jönsson will present the company at the investor conference BioCapitalEurope 2024, which is organized by EQT Life Sciences.

January 31, 2024
·
2 min read
Zymeworks Announces Participation in Upcoming Investor Conferences - Jan 31, 2024

Zymeworks Inc. announced that management will participate in the following upcoming investor conferences.

January 31, 2024
·
2 min read
FDA

Boston Scientific Receives FDA Approval for FARAPULSE™ Pulsed Field Ablation System

Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval for the FARAPULSE™ Pulsed Field Ablation (PFA) System.

January 31, 2024
·
7 min read
Business

Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2023 Results

Thermo Fisher Scientific Inc., the world leader in serving science, reported its financial results for the fourth quarter and full year ended December 31, 2023.

January 31, 2024
·
28 min read
Business

Cencora Reports Fiscal 2024 First Quarter Results

Cencora, Inc. reported that in its fiscal year 2024 first quarter ended December 31, 2023, revenue increased 15.0 percent year-over-year to $72.3 billion.

January 31, 2024
·
35 min read